In this review:
Doublet chemo benefits elderly with advanced NSCLC
Oral ALK inhibitor PF-02341066 in ALK-positive NSCLC
Nab-paclitaxel + carboplatin promising in NSCLC
Adjuvant gefitinib in resected NSCLC: no advantage
Erlotinib + BSC in poor PS advanced NSCLC
First-line
Please login below to download this issue (PDF)